STANDARD BIOTOOLS INC. — Director's Dealing 2022

Apr 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2022-04-04

Reporting Person: Casdin Eli (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-04	Common Stock	A	15852	—	Acquired	15852	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-04	Series B-1 Convertible Preferred Stock	$	A	127780	Acquired		Common Stock (37582346)	Indirect
2022-04-04	Stock Option (Right to Buy)	$3.99	A	23401	Acquired	2032-04-04	Common Stock (23401)	Direct

Footnotes

F1: Represents Restricted Stock Units that vest in four equal annual increments beginning April 4, 2023.

F2: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock.

F3: On April 4, 2022, the Issuer issued the Series B-1 Preferred Stock (i) in exchange for aggregate cash consideration of $112.5 million, pursuant to the Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, among the Issuer, Casdin Partners Master Fund, L.P. ("Casdin Master Fund") and Casdin Private Growth Equity Fund II, L.P. ("Casdin Private Growth Fund") and (ii) upon the conversion of $12.5 million aggregate principal amount of term loans, including accrued and unpaid interest, pursuant to the Series B-1 Loan Agreement, dated as of January 23, 2022, among the Issuer, Casdin Master Fund and Casdin Private Growth Fund.

F4: These shares are held by Casdin Master Fund and Casdin Private Growth Fund. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Master Fund and Casdin Private Growth Fund. Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Master Fund and Casdin Private Growth Equity Fund II GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Fund. Eli Casdin is the managing member of Casdin Capital, Casdin Partners GP and Casdin Private Growth GP. Each of Casdin Capital, Casdin Partners GP, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any.

F5: The Option becomes exercisable in four equal annual increments beginning on April 4, 2023.